Sarah-Catherine Rodan, Noah Meez, Sophie Lloyd-Hurwitz, Miguel A Bedoya-Pérez, Anastasia Suraev, Natasha Sommer, Kayla Greenstien, Sarah Maguire, Iain S McGregor
{"title":"患有饮食失调或饮食失调的个体使用致幻剂:来自国际MED-FED调查的结果。","authors":"Sarah-Catherine Rodan, Noah Meez, Sophie Lloyd-Hurwitz, Miguel A Bedoya-Pérez, Anastasia Suraev, Natasha Sommer, Kayla Greenstien, Sarah Maguire, Iain S McGregor","doi":"10.1186/s40337-025-01328-5","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>There are few effective treatments for eating disorders (EDs), and new interventions are urgently needed. The MEDication and other drugs For Eating Disorders (\"MED-FED\") survey investigated the lived experience of adults with EDs regarding their prescription and non-prescription drugs use. Psychedelic drugs were highly rated in this survey for their impact on ED symptoms and general mental health. Here, we provide a more granular analysis of a subset of the data pertaining to psychedelic drug use from this survey.</p><p><strong>Methods: </strong>The MED-FED survey recruited adults who self-reported either a clinically diagnosed ED or disordered eating that was currently undiagnosed but causing significant distress. The demographics of recent and lifetime psychedelic users relative to non-users were examined, as well as their use of other prescription and non-prescription drugs, and co-morbid conditions. Qualitative analysis was used to examine themes emerging from open-ended comments around use of psychedelic drugs.</p><p><strong>Results: </strong>Of the 5247 participants who completed the survey, 1699/5247 (32.4%) reported lifetime psychedelic use, with 1019/5247 (19.4%) having used in the last 12 months. Typical use involved infrequent consumption, once or twice per year, of psilocybin, LSD, 2-CB, or DMT. Those who reported recent psychedelic use were younger and less likely to currently use prescription drugs or to have been recently hospitalised for their ED. They were more likely to use other non-prescription drugs (e.g. cannabis, ketamine, stimulants) and to report co-morbid ADHD, PTSD, ASD, and substance misuse. Participants with a diagnosis of anorexia nervosa were less likely to report psychedelic use, while those with an undiagnosed ED were more likely. Qualitative analysis of responses (n = 200) revealed themes of profound transformation, increased connectedness, and new insights into illness following psychedelic experiences. A handful of respondents reported benefits from microdosing. A few respondents reported adverse outcomes in their open-ended comments, including \"bad trips\" (n = 15) and worsened ED symptoms (n = 8) after psychedelic use.</p><p><strong>Conclusions: </strong>These findings provide a unique insight into psychedelic use among individuals with EDs. The results align with emerging evidence suggesting that psychedelics may be beneficial in this population, highlighting the need for further research, including clinical trials, to explore their efficacy and safety.</p>","PeriodicalId":48605,"journal":{"name":"Journal of Eating Disorders","volume":"13 1","pages":"152"},"PeriodicalIF":4.5000,"publicationDate":"2025-07-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12288234/pdf/","citationCount":"0","resultStr":"{\"title\":\"Psychedelic use in individuals living with eating disorders or disordered eating: findings from the international MED-FED survey.\",\"authors\":\"Sarah-Catherine Rodan, Noah Meez, Sophie Lloyd-Hurwitz, Miguel A Bedoya-Pérez, Anastasia Suraev, Natasha Sommer, Kayla Greenstien, Sarah Maguire, Iain S McGregor\",\"doi\":\"10.1186/s40337-025-01328-5\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>There are few effective treatments for eating disorders (EDs), and new interventions are urgently needed. The MEDication and other drugs For Eating Disorders (\\\"MED-FED\\\") survey investigated the lived experience of adults with EDs regarding their prescription and non-prescription drugs use. Psychedelic drugs were highly rated in this survey for their impact on ED symptoms and general mental health. Here, we provide a more granular analysis of a subset of the data pertaining to psychedelic drug use from this survey.</p><p><strong>Methods: </strong>The MED-FED survey recruited adults who self-reported either a clinically diagnosed ED or disordered eating that was currently undiagnosed but causing significant distress. The demographics of recent and lifetime psychedelic users relative to non-users were examined, as well as their use of other prescription and non-prescription drugs, and co-morbid conditions. Qualitative analysis was used to examine themes emerging from open-ended comments around use of psychedelic drugs.</p><p><strong>Results: </strong>Of the 5247 participants who completed the survey, 1699/5247 (32.4%) reported lifetime psychedelic use, with 1019/5247 (19.4%) having used in the last 12 months. Typical use involved infrequent consumption, once or twice per year, of psilocybin, LSD, 2-CB, or DMT. Those who reported recent psychedelic use were younger and less likely to currently use prescription drugs or to have been recently hospitalised for their ED. They were more likely to use other non-prescription drugs (e.g. cannabis, ketamine, stimulants) and to report co-morbid ADHD, PTSD, ASD, and substance misuse. Participants with a diagnosis of anorexia nervosa were less likely to report psychedelic use, while those with an undiagnosed ED were more likely. Qualitative analysis of responses (n = 200) revealed themes of profound transformation, increased connectedness, and new insights into illness following psychedelic experiences. A handful of respondents reported benefits from microdosing. A few respondents reported adverse outcomes in their open-ended comments, including \\\"bad trips\\\" (n = 15) and worsened ED symptoms (n = 8) after psychedelic use.</p><p><strong>Conclusions: </strong>These findings provide a unique insight into psychedelic use among individuals with EDs. The results align with emerging evidence suggesting that psychedelics may be beneficial in this population, highlighting the need for further research, including clinical trials, to explore their efficacy and safety.</p>\",\"PeriodicalId\":48605,\"journal\":{\"name\":\"Journal of Eating Disorders\",\"volume\":\"13 1\",\"pages\":\"152\"},\"PeriodicalIF\":4.5000,\"publicationDate\":\"2025-07-24\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12288234/pdf/\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Journal of Eating Disorders\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1186/s40337-025-01328-5\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"NUTRITION & DIETETICS\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Eating Disorders","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s40337-025-01328-5","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"NUTRITION & DIETETICS","Score":null,"Total":0}
Psychedelic use in individuals living with eating disorders or disordered eating: findings from the international MED-FED survey.
Background: There are few effective treatments for eating disorders (EDs), and new interventions are urgently needed. The MEDication and other drugs For Eating Disorders ("MED-FED") survey investigated the lived experience of adults with EDs regarding their prescription and non-prescription drugs use. Psychedelic drugs were highly rated in this survey for their impact on ED symptoms and general mental health. Here, we provide a more granular analysis of a subset of the data pertaining to psychedelic drug use from this survey.
Methods: The MED-FED survey recruited adults who self-reported either a clinically diagnosed ED or disordered eating that was currently undiagnosed but causing significant distress. The demographics of recent and lifetime psychedelic users relative to non-users were examined, as well as their use of other prescription and non-prescription drugs, and co-morbid conditions. Qualitative analysis was used to examine themes emerging from open-ended comments around use of psychedelic drugs.
Results: Of the 5247 participants who completed the survey, 1699/5247 (32.4%) reported lifetime psychedelic use, with 1019/5247 (19.4%) having used in the last 12 months. Typical use involved infrequent consumption, once or twice per year, of psilocybin, LSD, 2-CB, or DMT. Those who reported recent psychedelic use were younger and less likely to currently use prescription drugs or to have been recently hospitalised for their ED. They were more likely to use other non-prescription drugs (e.g. cannabis, ketamine, stimulants) and to report co-morbid ADHD, PTSD, ASD, and substance misuse. Participants with a diagnosis of anorexia nervosa were less likely to report psychedelic use, while those with an undiagnosed ED were more likely. Qualitative analysis of responses (n = 200) revealed themes of profound transformation, increased connectedness, and new insights into illness following psychedelic experiences. A handful of respondents reported benefits from microdosing. A few respondents reported adverse outcomes in their open-ended comments, including "bad trips" (n = 15) and worsened ED symptoms (n = 8) after psychedelic use.
Conclusions: These findings provide a unique insight into psychedelic use among individuals with EDs. The results align with emerging evidence suggesting that psychedelics may be beneficial in this population, highlighting the need for further research, including clinical trials, to explore their efficacy and safety.
期刊介绍:
Journal of Eating Disorders is the first open access, peer-reviewed journal publishing leading research in the science and clinical practice of eating disorders. It disseminates research that provides answers to the important issues and key challenges in the field of eating disorders and to facilitate translation of evidence into practice.
The journal publishes research on all aspects of eating disorders namely their epidemiology, nature, determinants, neurobiology, prevention, treatment and outcomes. The scope includes, but is not limited to anorexia nervosa, bulimia nervosa, binge eating disorder and other eating disorders. Related areas such as important co-morbidities, obesity, body image, appetite, food and eating are also included. Articles about research methodology and assessment are welcomed where they advance the field of eating disorders.